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Abstract
Background: Influenza and respiratory syncytial virus (RSV) infection are common causes of lower respiratory tract
illness. Data on their burden in low and middle-income settings and from Africa are scarce. We aimed to estimate
age-specific rates of hospitalization attributable to influenza and RSV among patients attending private hospitals in
South Africa during 2007 2012.
Methods: We estimated annual age-specific rates of influenza- and RSV-associated hospitalization (that is respiratory
hospitalizations likely due to influenza or RSV infection) by applying regression models to monthly administrative
hospitalization data from a national private hospital group, using influenza and RSV surveillance data as covariates.
Results: Estimated mean hospitalization rates associated with seasonal influenza were 75 (95% confidence interval
(CI), 41 108) and 3 (95% CI, 2 5) per 100,000 person-years for all-respiratory and all-circulatory causes, respectively.
Children <1 year and adults ≥75 years were the most affected, with influenza-associated all-respiratory
hospitalization rates estimated at 255 (95% CI, 143 358) and 380 (95% CI, 227 506) per 100,000 person-years,
respectively. Excess all-circulatory hospitalizations associated with seasonal influenza were only observed in
adults ≥65 years. Annual hospitalization rates associated with RSV averaged an estimate of 223 (95% CI, 128 317)
per 100,000 person-years for all-respiratory causes. Among children <1 year, RSV-associated all-respiratory
hospitalization rate of 7,601 (95% CI, 4,312-10,817) per 100,000 person-years was estimated.
Conclusions: Influenza and RSV substantially contributed to hospitalizations over the study period.
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Background
In 2008, there were between 13 and 32 million cases of
pneumonia attributed to influenza virus infection globally,
with up to 110,000 deaths in children <5 years of age [1].
In the same age group, RSV infection accounted for 34
million hospitalizations and between 66,000 and 199,000
deaths [2]. The vast majority of these deaths likely due to
influenza (influenza-associated) and RSV (RSV-associated)
infection occurred in low and middle-income countries.
The burden of influenza- and RSV-associated hospitaliza-
tions across different age-groups has been well documented
in high-income countries [3-14]. However, such informa-
tion are limited in low and middle-income settings.
The influenza season in South Africa is well-defined
and occurs during the southern hemisphere winter
months (May to August) [15], while peak activity of RSV
is observed from February to May [16]. Recent estimates
of hospitalization burden associated with influenza and
RSV in South Africa are available only from one large
population-based surveillance site [16,17]. Since influenza
and RSV infections are rarely confirmed by laboratory
diagnosis we applied modeling approaches to estimate
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age-specific influenza- and RSV-associated hospitaliza-
tions among individuals hospitalized at a network of pri-
vate hospitals in South Africa from 2007 through 2012.
Methods
Hospitalization data
We obtained anonymized hospitalization data on admission
diagnoses, that were coded according to the International
Classification of Diseases, Tenth Revision (ICD-10), from a
large network of private hospitals covering seven of the
nine Provinces in South Africa (Eastern Cape, Free State,
Gauteng, KwaZulu-Natal, Mpumalanga, North West, and
Western Cape), for the period 2007 2012. We used
the ICD-10 codes to compile age-specific monthly
hospitalization time-series for all-respiratory (ICD-10:
J00-J99), pneumonia and influenza (P&I) (ICD-10: J10-J18
a subset of all-respiratory) and all-circulatory (ICD-10:I00-
I99)) hospitalizations. Hospitalization data were analyzed
in seven age categories: <1, 1 4, 5 19, 20 44, 45 64,
65 74 and ≥75 years of age.
Population denominators
We obtained countrywide annual population estimates
for each of the seven age-groups from Statistics South
Africa for the years 2007 2012 [18]. We calculated the
proportion of the population that had private health in-
surance by using available data on annual national health
insurance coverage [18]. We then standardized it to the
national population by age-group and health insurance
coverage, based on the age-grouping data provided by the
largest health insurance group in South Africa [19]. After
obtaining the age-standardized number of individuals with
private health insurance per year, we used annual market
share data to estimate the proportion registered to seek
care from the private hospital network under study. We es-
timated the private hospital group to have a market share
of 30% among the insured population, by computing their
reported annual number of hospital beds against the total
number of private hospital beds in the country for each of
the six years studied. The resulting market share was con-
sistent with previous independent reports on private hos-
pital market distribution in the country [20].
South Africa had an estimated population of 51.3 mil-
lion in 2012; 16% of the population had private healthcare
insurance, and the rest of the population sought care from
public sector health facilities [18]. For this study we esti-
mated the population served by the hospital group over
the study period to represent 4.5 to 5.1 percent (1.9-2.5
million people) of the South Africa population.
Influenza and RSV data
We acquired influenza and RSV virological data, for
the period 2007 2012, from a national database (the
National Health Laboratory Services (NHLS) corporate
data warehouse) that includes all patients tested for re-
spiratory viruses at any of the 268 networked public
health laboratories in South Africa. Data on influenza
type and subtype were not available from the national
database; these data were obtained from the National
Institute for Communicable Diseases (NICD)s Viral Watch
influenza surveillance programme, which receives samples
from health practitioners across the country [15]. We
considered an influenza type or subtype to be dominant
during the influenza season when it accounted for more
than 50% of the circulating viruses.
Estimation of influenza- and RSV-associated
hospitalizations
To estimate the influenza- (seasonal and pandemic) and
RSV-associated hospitalizations, we fitted age-specific
regression models with a Poisson distribution and an
identity link to monthly all-respiratory, all-circulatory
and P&I hospitalizations using methods previously de-
scribed [21]. The identity link was selected because it
is considered the most biologically plausible link to
model the impact of pathogen circulation on mortality
[22-25]. An identity link assumes additive (rather than
multiplicative) effects of different pathogens on mortality.
Through model selection procedures, we assessed the fit
of models including higher order polynomials to represent
more subtle time trends (1st to 6th degree) and additional
harmonic terms representing annual and semi-annual
periodicity (sin(2tiπ/12) and cos(2tiπ/12); sin(4tiπ/12)
and cos(4tiπ/12)). The final model was that for which
the Akaike value was minimized, that is, the model that
provided best fit to the data whilst maintaining parsimony.
Variations of <5% on model estimates were observed while
using a negative binomial model as compared to the
Poisson model; nonetheless the latter provided a better
fit to the data. We also considered b-splines (1 knot per
month was best) instead of polynomial terms to model
background seasonality but polynomial terms provided
the best fit to the South African data, perhaps because
of the relatively crude monthly resolution of the data.
The full model included covariates for time trends and
seasonal variation as well as viral circulation as follows:
E Y i;t
 
β0;i β1;i t β2;i t2 β3;i t3 β4;i t4
β5;i sin 2tπ=12  β6;i cos 2tπ=12 
β7;i Seasonal Influenza t 
β8;i A H1N1 pdm09 t  β9;i RSV t 
εi;t
1
E(Yi,t) represents age-specific number of deaths in age
group i and month t; β0,i is the age-specific model
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constant; β1,i to β4,i are age-specific coefficients associated
with time trends (linear to quartic polynomial terms);
β5,i and β6,i are age-specific coefficients associated with
harmonic terms accounting for annual background sea-
sonal variations; β7,i to β9,i are age-specific coefficients
representing the contribution of respiratory viruses to
mortality (seasonal influenza (β7,i): including A(H1N1),
A(H3N2) and B; pandemic influenza (β8,i): A(H1N1)
pdm09; and RSV (β9,i)); and εi,t is the age-specific error
term. Seasonal_influenza(t), A(H1N1)pdm09(t) and RSV
(t) are proxies for monthly viral activity, estimated as
the monthly number of specimen testing positive for
influenza or RSV over the annual number of specimens
tested for the specific pathogen. We used standardization
by the annual total of all specimens tested for the specific
pathogen to reduce possible bias associated with differ-
ences in specimen sampling and laboratory methods over
time [14,21].
To estimate the excess hospitalization associated with
influenza and RSV, we subtracted predicted monthly
hospitalizations from a full model incorporating all viral
terms from an expected baseline. The baseline was ob-
tained by setting the viral covariates to zero and the
annual excess hospitalizations were estimated as the
sum of the monthly excess hospitalizations for each
year. We obtained 95% confidence intervals (CI) for
the estimated excess hospitalizations using bootstrap
resampling on blocks of calendar years (12-month block
resampling with replacement) over 1000 replications
[21,26]. For each resampled dataset we refitted the Poisson
regression model and the 95% CI were obtained from
the 2.5th and 97.5th percentiles of the estimated
influenza- and RSV-associated hospitalizations from the
1000 resampled datasets. The statistical analysis was
implemented using STATA version 12 (StataCorp, Texas,
USA).
Ethical considerations
Since the analysis used only de-identified and aggregated
hospitalization and laboratory data, this study was consid-
ered to be exempt from human subjects ethics review.
Results
Rates of hospitalization
South Africa had a population of approximately 51.3
million people in 2012. Over the study period, an annual
mean of 530,345 hospitalizations (range 491,155-576,634)
across all age-groups occurred in the private hospital
network for all causes, of which 51,899 (10%) were at-
tributed to respiratory causes and 28,904 (6%) to circu-
latory causes. The mean annual rates of all-respiratory
and P&I causes of hospitalization were highest in the <1
and ≥75 year age-groups and lowest in the 20 44 year
age-group (Table 1). The rates of hospitalization attributed
to circulatory illness increased with increasing age and
were highest among those ≥75 years of age.
Influenza and RSV laboratory surveillance
Means of 8,922 (range 4,720-15,321) and 6,640 (range
2,637-10,331) samples were tested annually for influ-
enza and RSV, respectively. The mean annual number
of specimens testing positive was 2,099 (23%) for in-
fluenza virus and 1,194 (18%) for RSV. During the
study period, the influenza season peaked between
June and August, while RSV peak activity was ob-
served between February and April (Figure 1A). In
2009, a first wave of influenza peaked in June and was
mainly due to A(H3N2), followed by a second influ-
enza wave that peaked in August and was caused by A
(H1N1)pdm09.
Influenza- and RSV-associated hospitalizations
The estimated annual rates of all-respiratory hospitali-
zations attributed to seasonal influenza (excluding A
(H1N1)pdm09) ranged from 54.2 to 111.9 per 100,000
person-years (Table 2). Annual circulatory hospitaliza-
tions associated with influenza were estimated to range
from 2.3 to 4.8 per 100,000 person-years. Rates of
RSV-associated hospitalizations among the <20 year
age-group ranged from 195.9 to 262.7 per 100,000
person-years for all-respiratory illnesses over the study
period.
Estimated mean annual all-respiratory hospitalization
rates associated with seasonal influenza were highest
among children aged <1 year (255 per 100,000 person-
years) and individuals aged ≥75 years (380 per 100 000
person years) (Table 3). Seasonal influenza-associated
all-circulatory hospitalizations were only estimated among
individuals ≥65 years of age.
In 2009 the estimated rate of all-respiratory hospital-
izations associated with influenza A(H1N1)pdm09 was
136 per 100,000 person-years, almost two times higher
than the mean influenza-associated hospitalizations
during non-pandemic years (Table 3). The rates of hos-
pitalizations associated with influenza A(H1N1)pdm09
among individuals >5 years of age were higher than
mean seasonal influenza hospitalization rates (espe-
cially in the 5 19 age group), but lower among elderly
individuals.
The estimated mean annual rates of RSV-associated
all-respiratory hospitalizations decreased with age; and it
was highest among <1 year age-group (7,601 per 100,000
person-years) and lowest among 5 19 year age-group
(57 per 100,000 person-years) (Table 3). Similar trends
were observed among pneumonia and influenza cases
that were associated with RSV. Our model did not
estimate any RSV-associated hospitalizations among
individuals ≥20 years of age.
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Discussion
Influenza and RSV substantially contributed to hospital-
izations in South Africa throughout the study period.
Hospitalization rates associated with seasonal influenza
were highest among children <1 year of age and individuals
aged ≥75 years, while RSV mostly affected children <5 years
of age. We did not estimate any RSV-associated hospitali-
zations among individuals aged ≥20 years.
Elevated influenza-associated hospitalizations have
been reported among infants and elderly individuals in
other studies conducted in the United States and Europe
[8,13,14]. Estimated rates of influenza-associated hos-
pitalizations per 100,000 person-years in South Africa
among children <1 (255) and 1 4 (205) years of age for
all-respiratory causes were elevated, compared with
the United States (151 in children <1 year of age and
39 among children 1 4 years of age for respiratory and
circulatory cause of hospitalization) [14]. Estimated rates of
influenza-associated P&I hospitalizations (41 per 100,000
person-year) observed in our study were similar to esti-
mates of influenza-associated hospitalizations (49 and 54
per 100,000 person-year in 2010 and 2011, respectively)
derived from a large population-based public hospital
surveillance site in Soweto, South Africa, where patients
presenting with acute lower respiratory tract infection
were systematically enrolled and tested for influenza from
2009 through 2011 [17].
Rates of influenza A(H1N1)pdm09-associated all-
respiratory hospitalizations in 2009 in South Africa
were estimated to be approximately double those ob-
served during non-pandemic years and disproportionately
affected young individuals (especially the 5 19 year
age-group), with the elderly being the least affected.
Studies on the 2009 influenza pandemic previously con-
ducted in the United States [27,28], Canada [29], Argentina
[30] and Italy [31] observed similar patterns.
We identified an elevated burden of RSV compared to
influenza infection among children <5 years of age. A
study conducted in children aged <5 years with respira-
tory infections that attended public sector hospitals in
South Africa showed a 30% positivity proportion for
RSV compared to only 4% for influenza [32]. Another
study conducted in the United States using a methodology
similar to ours found RSV-associated hospitalizations to
be 16 times higher than influenza among children <1 year
of age [14,33]. In our study, estimated mean annual rates
per 100,000 person-years of RSV-associated P&I hospi-
talizations among children <1 (3,055) and 1 4 (457)
years of age were similar to those observed from a
population-based surveillance site in Soweto, South
Africa, in 2010 2011 (2,400-3,200 in children <1 year
of age and 500 600 in children aged 1 4 years) [16].
Our model did not estimate any excess hospitalizations
associated with RSV among elderly individuals, although
other studies have previously reported morbidity and mor-
tality among adults infected with laboratory-confirmed
RSV [34,35]. Studies conducted in Kenya and South Africa
that compared the RSV prevalence among patients hos-
pitalized with severe acute respiratory illness (SARI) to
controls found that RSV infection was associated with
hospitalization among children <5 years of age, but no
association was found among individuals ≥5 years old
[36,37]. Studies conducted in Egypt, Guatemala, Kenya
and Thailand, where patients of all ages hospitalized
Table 1 Mean annual hospitalization rates and population at risk among individuals with health insurance and served








Pneumonia and influenzac Circulatoryd
Mean annual ratese (rangef) Mean annual ratese (rangef) Mean annual ratese (rangef)
<1 39529 (33009 43103) 29043 (25500 32697) 11542 (10148 13236) 226 (186 300)
1-4 162117 (132038 180020) 6083 (4741 7496) 1663 (1359 1846) 38 (30 46)
5-19 478789 (405825 519777) 2176 (1887 2564) 433 (337 519) 152 (139 187)
20-44 996137 (838835 1082658) 1322 (1172 1594) 409 (359 467) 841 (772 1036)
45-64 494431 (413592 534990) 2026 (1800 2293) 718 (623 781) 3795 (3511 4570)
65-74 103672 (79611 118082) 3742 (3434 4521) 1417 (1324 1718) 8677 (7546 10894)
≥75 48562 (26893 54317) 7507 (6595 9327) 3873 (3483 4773) 15175 (13990 18814)
All 2323237 (1929803 2532947) 2393 (2181 2767) 709 (654 778) 1938 (1795 2287)
aDetermined by calculating proportion of age-specific population with health insurance, who are served by the hospital group under study, based on their market
share estimates.
bHospitalized with a diagnosis of International Classification of Diseases Tenth Revision (ICD-10) codes of J00-J99.
cHospitalized with a diagnosis of ICD-10: J10-J18.
dHospitalized with a diagnosis of ICD-10: I00-I99.
eHospitalization rate per 100,000 person-years.
fRate ranges over the six years studied, 2007 to 2012.




























































































Figure 1 (See legend on next page.)
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with acute lower-respiratory tract infections were sys-
tematically enrolled and tested using molecular tech-
niques, reported RSV detection rates of <1-5% among
individuals ≥50 or ≥65 years of age compared to RSV
detection rates of >20% in infants and young children
[38-40]. In South Africa in 2009 2010, the RSV detec-
tion rate among patients hospitalized with SARI de-
creased from 26.8% among infants <1 year of age to
0.9% among individuals ≥65 years, compared with an
influenza detection rate of approximately 8-12% across
all age groups in the same study population [33]. This
may suggest that although RSV can be detected among
older children and adults, it may play a less important
role as a pathogen in this group.
A recent study conducted to estimate adult mortality
associated with influenza and RSV in South Africa (using
a methodology similar to ours) found only influenza- and
not RSV-associated mortality among individuals older
than 44 years of age [41]. While cases of RSV-associated
hospitalization and mortality among elderly individuals
are expected to occur in South Africa, our modelling
approach may have failed to statistically estimate a small
number of cases. Other national estimates of influenza-
and RSV-associated mortality among adult and elderly
individuals have been determined mainly using modelling
approaches similar to ours and in settings where the
influenza and RSV seasons are more synchronous [7,42].
Ecological studies conducted in settings similar to ours,
(See figure on previous page.)
Figure 1 Monthly detection of influenza and respiratory syncytial virus and hospitalization rates among individuals attending private
hospitals in South Africa, 2007 2012. A: Detection rate (i.e., monthly number of positive specimens divided by total specimens) of influenza
and respiratory syncytial virus (all ages). B: Observed all-respiratory hospitalizations and predicted hospitalizations and baseline (Poisson model) by
month in children <1 year of age. C: Observed all-respiratory hospitalizations and predicted hospitalizations and baseline (Poisson model) by
month in individuals ≥75 years of age.
Table 2 Annual variation in influenza types/subtypes and estimated annual influenza- and respiratory syncytial
virus-associated hospitalizations among individuals (all ages) attending a private hospital group in South Africa,
2007 2012
Year Estimated hospitalizations
Influenza (excluding A(H1N1)pdm09 in 2009) RSV
Dominant type/subtype Numbera Rateb Numbera Rateb
All-respiratory (including pneumonia and influenza)
2007 A (H3N2) 2151 112 5098 263
2008 A (H1N1) 1707 73 4889 207
2009 A (H3N2) 1934 79 6432 261
2010 B 1660 66 4987 197
2011 A (H1N1)pdm09 1637 72 4475 196
2012 A (H3N2) 1282 54 5112 216
Pneumonia and influenza only
2007 A (H3N2) 1136 57 2011 102
2008 A (H1N1) 902 37 1929 80
2009 A (H3N2) 1022 41 2538 101
2010 B 877 34 1968 76
2011 A (H1N1)pdm09 865 37 1766 75
2012 A (H3N2) 677 28 2017 83
All-circulatory
2007 A (H3N2) 92 5
2008 A (H1N1) 73 3
2009 A (H3N2) 83 3
2010 B 71 3
2011 A (H1N1)pdm09 70 3
2012 A (H3N2) 55 2
aEstimated number of patients served in the private hospital group per cause of hospitalization per year.
bHospitalization rate per 100,000 person-years.
Kyeyagalire et al. BMC Infectious Diseases 2014, 14:694 Page 6 of 10
http://www.biomedcentral.com/1471-2334/14/694
Table 3 Estimated mean annual influenza- and respiratory syncytial virus-associated hospitalizations by age group among individuals attending a private
hospital group in South Africa, 2007 2012
Age groups
(in years)
Influenza (mean) Respiratory syncytial virus (Mean)























<1 99 (56 142) 255 (143 358) 1.2 (0.8-1.6) 260 (148 372) 621 (354 888) 3.1 (2.2-4.0) 2990 (1704 4276) 7601 (4312 10817) 36.2 (25.3-47.1)
1-4 326 (196 456) 205 (121 282) 4.3 (3.0-5.6) 197 (118 276) 116 (70 162) 2.4 (1.7-3.1) 1902 (1141 2663) 1182 (704 1643) 25.7 (17.7-33.7)
5-19 261 (117 405) 55 (25 84) 2.7 (1.9-3.5) 1183 (532 1834) 233 (105 361) 11.8 (8.1-15.5) 272 (122 422) 57 (26 88) 2.8 (1.9-3.7)
20-44 366 (179 553) 37 (18 55) 2.9 (2.0-3.8) 922 (452 2392) 87 (43 131) 7.0 (4.8-9.2)
45-64 341 (198 484) 70 (40 98) 3.5 (2.3-4.7) 588 (341 835) 112 (65 159) 5.9 (3.8-8.0)
65-74 154 (92 216) 154 (89 208) 4.1 (2.6-5.6) 148 (89 207) 139 (73 163) 4.0 (2.5-5.5)
75+ 178 (110 246) 380 (227 506) 5.2 (3.5-6.9) 61 (38 84) 117 (73 163) 1.7 (1.1-2.3)
All 1725 (949 2501) 75 (41 108) 3.1 (2.2-4.0) 3359 (1718 5001) 136 (70 203) 5.9 (4.1-7.7) 5164 (2968 7360) 223 (128 317) 9.3 (6.4-12.2)
Pneumonia and influenza
<1 94 (54 134) 241 (136 340) 6.9 (4.8-9.0) 204 (116 292) 488 (278 697) 12.2 (8.5-15.9) 1201 (685 1717) 3055 (1732 4345) 34.6 (24.2-45.0)
1-4 125 (75 175) 78 (46 108) 8.1 (5.6-10.6) 187 (112 262) 110 (66 154) 13.5 (9.3-17.7) 735 (441 1029) 457 (272 635) 25.9 (17.9-33.9)
5-19 129 (58 200) 27 (12 42) 7.6 (5.2-10.0) 678 (305 1051) 133 (60 207) 38.9 (26.8-51.0) 100 (45 155) 21 (9 32) 5.9 (4.1-7.7)
20-44 198 (97 299) 20 (10 30) 7.2 (4.9-9.5) 481 (236 726) 45 (22 69) 12.0 (8.2-15.8)
45-64 195 (113 277) 40 (23 56) 7.8 (5.1-10.5) 278 (161 395) 53 (31 75) 8.1 (5.3-10.9)
65-74 85 (51 119) 85 (49 115) 6.1 (3.8-8.4) 83 (50 116) 78 (47 110) 5.9 (3.7-8.1)
75+ 120 (74 166) 256 (153 341) 6.9 (4.6-9.2) 29 (18 40) 56 (35 77) 2.1 (1.4-2.8)







65-74 23 (10 36) 23 (10 34) 0.2 (0.1-0.3) 91 (55 127) 86 (52 120) 1.0 (0.6-1.4)
75+ 50 (25 75) 107 (51 154) 0.7 (0.5-0.9) 14 (9 19) 28 (17 37) 0.2 (0.1-0.3)
All 73 (35 111) 3 (2 5) 0.1 (0.06-0.14) 105 (63 147) 4 (3 6) 0.1 (0.5-0.15)



















where influenza and RSV peak activities are not synchron-
ous, may assist in better differentiating the relative burden
of these pathogens especially in adults. While in our study
we report low to moderate RSV-associated hospitalization
among individuals ≥5 years of age, clinical diagnosis and
surveillance for both influenza and RSV should be contin-
ued and strengthened, and may be leveraged to better
understand the burden and severity associated with RSV
infection in older age groups.
Our study has limitations that warrant discussion.
Firstly, the lack of weekly hospitalization data may have
hindered the ability to more accurately estimate the
relative contribution of RSV and influenza virus on
hospitalizations. In addition, the monthly temporal
resolution of our data did not allow us to include viral
circulation proxies for each season. Our approach may
underestimate the annual variation of influenza-associated
hospitalizations in our study. Secondly, lack of availability
of influenza and RSV incidence data hampered our ability
to consider more refined indicators of respiratory virus ac-
tivity in our time series models as reported by Goldstein
et al. [25,26]. Thirdly, we were not powered to estimate
the association of influenza and RSV circulation with
more refined causes of hospitalization. In addition, data
on the circulation of respiratory viruses other than influ-
enza and RSV were not available for the entire study
period and were not included in our study. This may
potentially overestimate the hospitalizations attributed to
influenza or RSV infection. Nonetheless, the estimates ob-
tained in our study are similar to those obtained from
case-based studies in South Africa [16,17]. Furthermore
case-based surveillance implemented among patients hos-
pitalized with severe acute respiratory illness (SARI) in
South Africa from 2009 indicated peak activities of human
metapneumovirus and parainfluenza virus type 3 after the
influenza season (September to November) with an an-
nual detection rate among SARI cases of approximately
4% for each pathogen. Given the different seasonality
of these pathogens minimal effect is expected on the
influenza- and RSV-associated hospitalizations estimated
with our model. All other respiratory viruses tested under
the SARI surveillance programme (e.g. adenovirus, entero-
virus, parainfluenza virus types 1 and 2, and rhinovirus)
were detected year-around without clear seasonality [33].
Fourthly, we could only estimate influenza- and RSV-
associated hospitalization using data from a proportion of
private hospitals in South Africa as national hospitalization
data, from all private and public health facilities, were not
available. In addition we estimated the service population
of the hospital group used in this study based on available
data on number of individuals insured and market share
of this hospital group. The representativeness of our esti-
mations for national population is therefore uncertain.
Nonetheless, our incidence rate estimates were similar to
those obtained using active, prospective surveillance
from a large population-based public sentinel hospital
[16,17], and may be reasonably representative of the
total population.
Conclusion
Our study found that influenza and RSV were associated
with substantial hospitalization rates in South Africa, with
influenza responsible for hospitalizations across all age-
groups and RSV affecting mainly individuals <5 years of
age. Vaccination remains the most effective method of
preventing influenza virus infection [43], and the effective-
ness of RSV candidate vaccines is being evaluated [44,45]
and when available could potentially substantially reduce
the elevated burden of hospitalization especially in young
children.
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